Meropenem . (Meropenem Trihydrate)

• Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.
• Complicated intra‑abdominal infection: achieves effective bacterial clearance in the abdominal cavity.
• Complicated urinary tract infection: eradicates resistant uropathogens in the urinary tract.
• Hospital‑acquired pneumonia: provides coverage against multidrug‑resistant respiratory pathogens.
• Ventilator‑associated pneumonia: treats ventilator‑related lung infections.
• Meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria.
• Sepsis and febrile neutropenia: offers rapid bactericidal activity in systemic infections.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins. This binding disrupts the final stages of peptidoglycan cross‑linking, leading to weakened cell walls and osmotic lysis of susceptible bacteria, including many gram‑negative and gram‑positive organisms resistant to other β‑lactams.

Adverse reactions to meropenem may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis during or after infusion.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema or pruritus.
• Infusion site phlebitis: irritation at the intravenous site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe allergic reaction requiring immediate intervention.
• Clostridioides difficile‑associated diarrhea: colitis due to gut flora disruption.
• Neutropenia: reduced white blood cell count.
• Thrombocytopenia: decreased platelet levels.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

• When using meropenem, clinicians should consider several safety and handling measures.
• Renal impairment: adjust dose based on creatinine clearance.
• History of seizures: monitor neurologic status closely.
• Pregnancy: category B, use only if benefit outweighs risk.
• Concurrent valproic acid therapy: monitor for reduced antiepileptic levels.
• Potential C. difficile infection: observe for new-onset diarrhea.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can affect or be affected by other medicines.

Major Interactions (Avoid)

• Valproic acid: may reduce antiepileptic serum concentrations.
• Probenecid: can increase meropenem plasma levels, raising toxicity risk.
• Cytotoxic agents (e.g., cyclophosphamide): heightened risk of myelosuppression.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxic potential.
• Loop diuretics: monitor renal function and electrolytes.
• Warfarin: observe INR for possible anticoagulation changes.
• Oral contraceptives: possible reduction in contraceptive efficacy.